Atossa Genetics Inc. (ATOS) Sets All-Time Low at $2.21

June 29, 2018 - By Skott Medlock

Atossa Genetics Inc. (NASDAQ:ATOS) Corporate Logo

Atossa Genetics Inc. (NASDAQ:ATOS) touched all time low on Jun, 29 touching $2.21. Our target is $2.06. announced it. The company has $6.22 million market cap. The company’s valuation will be $435,470 less at $2.06 target.

Ticker’s shares touched $2.21 during the last trading session after 3.07% change.Currently Atossa Genetics Inc. is downtrending after 41.40% change in last June 29, 2017. ATOS has also 123,725 shares volume. ATOS underperformed the S&P 500 by 53.97%.

Atossa Genetics Inc. (NASDAQ:ATOS)’s quarterly earnings will be announced on August, 13., Faxor reports. Last year’s earnings per share was $-7.68, while now analysts expect change of 90.36 % up from current $-0.74 earnings per share. Analysts at Wall Street see Atossa Genetics Inc.’s 4.23 % negative EPS growth compared to $-0.71 earnings per share for last quarter.

Atossa Genetics Inc. (NASDAQ:ATOS) Ratings Coverage

In total 2 analysts cover Atossa Genetics (NASDAQ:ATOS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:ATOS)’s analyst reports since January 26, 2018 according to StockzIntelligence Inc. The stock rating was initiated by Maxim Group with “Buy” on Friday, January 26.

For more Atossa Genetics Inc. (NASDAQ:ATOS) news posted briefly go to:,,, or The titles are as follows: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” posted on June 15, 2018, “Atossa Genetics (ATOS) Announces Opening of Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast …” on June 26, 2018, “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” with a publish date: June 19, 2018, “Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board” and the last “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with publication date: June 29, 2018.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States.The firm is worth $6.22 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions.Currently it has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: